Drugs / ZX-101A
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT05258266 | Mar 2022 → Jun 2023 | neoplasm | Nanjing Zenshine Pharmaceuticals | Unknown | No outcome recorded |
| Phase 1/2 | NCT05269940 | Feb 2022 → Jan 2023 | chronic lymphocytic leukemia/small lymphocytic lymphoma, peripheral T-cell lymphoma, not otherwise specified | Nanjing Zenshine Pharmaceuticals | Completed | No outcome recorded |
| Phase 1/2 | NCT04504708 | Feb 2021 → Jul 2022 | chronic lymphocytic leukemia/small lymphocytic lymphoma | Hangzhou Zenshine Pharmaceuticals Co., Ltd. | Terminated | No outcome recorded Stop: Business |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ZX-101A | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04504708 ↗ |
| Route | Oral | “administered orally once daily in 28-day cycles” NCT04504708 ↗ |